Cargando…

1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis

BACKGROUND: Patients with a penicillin (pcn) allergy are less likely to receive cefazolin (cef) and more likely to receive vancomycin (vanco) or clindamycin (clinda) for procedures. Literature reveals a 51% increased risk of surgical site infection in patients with a reported pcn allergy attributed,...

Descripción completa

Detalles Bibliográficos
Autores principales: Veach, Lisa A, Bushman, Amanda, Wall, Geoff, Hadziric, Adela, Olstinke, Kayla, Blackmer, Sydney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678620/
http://dx.doi.org/10.1093/ofid/ofad500.1299
_version_ 1785150405758418944
author Veach, Lisa A
Bushman, Amanda
Wall, Geoff
Hadziric, Adela
Olstinke, Kayla
Blackmer, Sydney
author_facet Veach, Lisa A
Bushman, Amanda
Wall, Geoff
Hadziric, Adela
Olstinke, Kayla
Blackmer, Sydney
author_sort Veach, Lisa A
collection PubMed
description BACKGROUND: Patients with a penicillin (pcn) allergy are less likely to receive cefazolin (cef) and more likely to receive vancomycin (vanco) or clindamycin (clinda) for procedures. Literature reveals a 51% increased risk of surgical site infection in patients with a reported pcn allergy attributed, in multivariable analysis, to use of second line antimicrobial agents. METHODS: We conducted a retrospective review of intravenous vanco and clinda administration in procedural areas during a 6 -month period in 2022. The aim of our study was to assess the appropriateness of the procedural prophylaxis antibiotic given based on the allergy information available in the medical record. Documented allergy responses were classified as: severe, cutaneous and other. Multiple documented reactions were classified using the most severe reaction type. RESULTS: Seven hundred and eighty-eight patient encounters were reviewed: 434 encounters receiving vanco and 354 encounters receiving clinda. Of the encounters receiving vanco, 237 (55%) had documentation of beta lactam allergy (pcn allergy (212), cef allergy (64), both (39)). Within the pcn allergy group, reaction was cutaneous only in 47% (100). In 79 encounters previous receipt of a cephalosporin was documented in the EHR. Of the encounters receiving clinda, 330 (93%) had documentation of a beta lactam allergy (pcn allergy (277), cef allergy (98), both (45)). Within the pcn allergy group, reaction was cutaneous only in 60% (167). In 109 encounters previous receipt of a cephalosporin was documented in the EHR. (Figures 1 and 2) In both groups nursing placed the majority of the vanco (69%) and clinda (70%) orders. [Figure: see text] [Figure: see text] CONCLUSION: At least 55% (N=267) of pcn allergic patients could have received the optimal agent (cefazolin) for procedural prophylaxis as they had only a cutaneous reaction. EHR review for prior cephalosporin administration in non-cutaneous reaction further increases that number. In recognition of the role of nursing, our health system has developed guidance documents to aid pre-op nursing staff in selecting the appropriate surgical prophylaxis antimicrobial in patients reporting pcn allergy. This document is readily available and shared with key stakeholders. Process improvement opportunities are ongoing. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678620
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106786202023-11-27 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis Veach, Lisa A Bushman, Amanda Wall, Geoff Hadziric, Adela Olstinke, Kayla Blackmer, Sydney Open Forum Infect Dis Abstract BACKGROUND: Patients with a penicillin (pcn) allergy are less likely to receive cefazolin (cef) and more likely to receive vancomycin (vanco) or clindamycin (clinda) for procedures. Literature reveals a 51% increased risk of surgical site infection in patients with a reported pcn allergy attributed, in multivariable analysis, to use of second line antimicrobial agents. METHODS: We conducted a retrospective review of intravenous vanco and clinda administration in procedural areas during a 6 -month period in 2022. The aim of our study was to assess the appropriateness of the procedural prophylaxis antibiotic given based on the allergy information available in the medical record. Documented allergy responses were classified as: severe, cutaneous and other. Multiple documented reactions were classified using the most severe reaction type. RESULTS: Seven hundred and eighty-eight patient encounters were reviewed: 434 encounters receiving vanco and 354 encounters receiving clinda. Of the encounters receiving vanco, 237 (55%) had documentation of beta lactam allergy (pcn allergy (212), cef allergy (64), both (39)). Within the pcn allergy group, reaction was cutaneous only in 47% (100). In 79 encounters previous receipt of a cephalosporin was documented in the EHR. Of the encounters receiving clinda, 330 (93%) had documentation of a beta lactam allergy (pcn allergy (277), cef allergy (98), both (45)). Within the pcn allergy group, reaction was cutaneous only in 60% (167). In 109 encounters previous receipt of a cephalosporin was documented in the EHR. (Figures 1 and 2) In both groups nursing placed the majority of the vanco (69%) and clinda (70%) orders. [Figure: see text] [Figure: see text] CONCLUSION: At least 55% (N=267) of pcn allergic patients could have received the optimal agent (cefazolin) for procedural prophylaxis as they had only a cutaneous reaction. EHR review for prior cephalosporin administration in non-cutaneous reaction further increases that number. In recognition of the role of nursing, our health system has developed guidance documents to aid pre-op nursing staff in selecting the appropriate surgical prophylaxis antimicrobial in patients reporting pcn allergy. This document is readily available and shared with key stakeholders. Process improvement opportunities are ongoing. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678620/ http://dx.doi.org/10.1093/ofid/ofad500.1299 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Veach, Lisa A
Bushman, Amanda
Wall, Geoff
Hadziric, Adela
Olstinke, Kayla
Blackmer, Sydney
1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis
title 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis
title_full 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis
title_fullStr 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis
title_full_unstemmed 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis
title_short 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis
title_sort 1462. analysis of clindamycin and vancomycin use and reported beta lactam allergy in procedural antimicrobial prophylaxis
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678620/
http://dx.doi.org/10.1093/ofid/ofad500.1299
work_keys_str_mv AT veachlisaa 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis
AT bushmanamanda 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis
AT wallgeoff 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis
AT hadziricadela 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis
AT olstinkekayla 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis
AT blackmersydney 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis